Kenya’s scientists have finally developed a vaccine to cure or stop HIV infection. There are going to launch human trials vaccine and said the researcher; they will recruit the patients in three weeks.
The vaccine is a block approach to prevent HIV infection. The vaccine works when it attaches with human cells and prevent the virus.
As you know, HIV infection spreads through bodily fluids. It attacks immune system cells called T cells.
“This clinical trial is called IAVI W001 trial.664gp140. Woo1 will test the vaccine named BG505 SOSIP. Researchers say the vaccine molecules have resemblance with human immunodeficiency T virus. It will check on volunteers for the efficacy.”
Prof Omu Anzala is the director of Kenya AIDS Vaccine Initiative “He conducted the phase one trial on the first human for this vaccine. This trial will answer questions on how safe the vaccine and how helpful to induce the human body antibodies that can neutralize HIV.”
Moreover, Dr. Elise Landais is a senior scientist in New York. She developed the molecule which is using in the HIV vaccine.
Furthermore, She explained the vaccine is a new generation of immunogens that can generate an immune response in the human body. It produces antibodies which attack the HIV.